药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02268 药明合联

已收盘 09-30 16:08:27

82.000

+3.950

+5.06%

最高82.350	最低78.000	成交量549.79万
今开78.050	昨收78.050	日振幅5.57%
总市值1,040亿	流通市值1,040亿	总股本12.68亿
成交额4.48亿	换手率0.43%	流通股本12.68亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":82,"timestamp":1790755707007,"preClose":78.05,"halted":0,"volume":5497939,"delay":0,"changeRate":0.05060858424087127,"floatShares":1268000000,"shares":1268000000,"eps":1.119999,"marketStatus":"已收盘","change":3.95,"latestTime":"09-30 16:08:27","open":78.05,"high":82.35,"low":78,"amount":447827810,"amplitude":0.055734,"askPrice":82.05,"askSize":11000,"bidPrice":82,"bidSize":8500,"shortable":3,"etf":0,"ttmEps":1.393408732,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790904600000},"marketStatusCode":5,"adr":0,"listingDate":1700150400000,"exchange":"SEHK","adjPreClose":78.05,"openAndCloseTimeList":[[1790731800000,1790740800000],[1790744400000,1790755200000]],"volumeRatio":1.211491,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02268","defaultTab":"news","newsList":[{"id":"2671222418","title":"创新药概念普涨 金斯瑞生物科技（01548）涨超10% 机构看好创新药及其产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=2671222418","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671222418?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:35","pubTimestamp":1790735739,"startTime":"0","endTime":"0","summary":"金吾财讯  | 创新药概念普涨，截至发稿，金斯瑞生物科技 涨10.10%，石药集团涨6.07%，云顶新耀涨5.79%，恒瑞医药涨5.18%，药明合联涨4.48%，晶泰控股涨4.06%，乐普生物涨3.52%，药明生物涨3.46%。消息面上，开源证券表示，整体上，持续看好创新药及其产业链及AI、脑机接口、生物制造等国家战略新兴产业。后续可重点跟踪ESMO临床数据、三季度订单及业绩验证和政策细则落地，积极把握优质创新药、CXO及生命科学上游调整后的配置机会。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992823","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0039217434.USD","01276","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","LU0708995153.HKD","02269","BK1574","LU1242518931.SGD","KURE","02228","IE00B0JY6N72.USD","IBBQ","SG9999004220.SGD","BK1589","LNGR","BK1515","LU1328277881.USD","LU1688375341.USD","LU1813983027.USD","LU0359201885.HKD","LU1188198961.HKD","LU0880133367.SGD","LU1242518857.USD","159992","LU0823426480.USD","LU0348827113.USD","02157","LU1226288170.HKD","LU1008478684.HKD","LU0029874905.USD","02268","LU1880383366.USD","01548","LU0128522744.USD","MEDX","06978","01952","LU0540923850.HKD","HK0000306701.USD","BK1161","LU0307460666.USD","LU0140636845.USD","LU1807302812.USD","BK1141","LU0072913022.USD","BK1521","LU0181495838.USD","LU0516422366.SGD","01093","BK1610"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167325366","title":"异动解读｜药明合联盘中上涨3.01%，板块集体反弹叠加对外投资扩张","url":"https://stock-news.laohu8.com/highlight/detail?id=1167325366","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167325366?lang=zh_cn&edition=full","pubTime":"2026-09-30 09:35","pubTimestamp":1790732124,"startTime":"0","endTime":"0","summary":"9月30日，药明合联盘中上涨3.01%，报80.45港元，成交额1888.11万港元。消息面上，公司新增一起对外投资，以60.67%的持股比例投资东曜药业股份有限公司，进一步拓展ADC相关CDMO业务版图。板块方面，生命科学工具和服务行业今日集体走强，此前连续承压的板块迎来反弹，同业个股金斯瑞生物科技涨5.51%，英矽智能涨3.70%，药明生物涨2.24%，药明康德涨1.64%，板块联动共振提振市场情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明合联上涨，对外投资拓展ADC版图","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158276591","title":"异动解读｜药明合联盘中下跌3.34%，大股东减持余波与板块承压共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1158276591","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158276591?lang=zh_cn&edition=full","pubTime":"2026-09-29 10:49","pubTimestamp":1790650191,"startTime":"0","endTime":"0","summary":"9月29日，药明合联盘中下跌3.34%，报76.6港元，成交额1.96亿港元。消息面上，药明康德8月底通过大宗交易出售药明合联5352.4万股，持股比例由18.36%降至14.14%，涉资约39.2亿港元，大股东集中减持对市场情绪的压制效应仍在持续发酵。板块方面，生命科学工具和服务行业今日整体走弱，同业个股金斯瑞生物科技跌4.48%，药明生物跌1.69%，板块联动进一步放大跌幅。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药明合联盘中下跌，大股东减持余波持续压制","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178964798","title":"异动解读｜药明合联盘中下跌3.02%，生命科学板块集体承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1178964798","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178964798?lang=zh_cn&edition=full","pubTime":"2026-09-28 09:40","pubTimestamp":1790559605,"startTime":"0","endTime":"0","summary":"9月28日，药明合联盘中下跌3.02%，报78.75港元，成交额3011.8万港元。板块方面，生命科学工具和服务行业今日整体走弱，同业个股中金斯瑞生物科技跌3.91%，药明康德跌1.53%，药明生物跌0.66%。股东变动方面，药明康德8月底通过大宗交易出售药明合联5352.4万股，持股比例由18.36%降至14.14%，涉资约39.2亿港元，大股东集中减持对市场情绪的影响仍在持续。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药明合联盘中下跌，大股东减持持续施压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670470289","title":"高盛：药明合联给予“买入”评级 目标价97.90港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670470289","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670470289?lang=zh_cn&edition=full","pubTime":"2026-09-27 12:39","pubTimestamp":1790483940,"startTime":"0","endTime":"0","summary":"模拟交易客户端高盛发布研报称，给予药明合联“买入”评级，目标价97.9港元，对应预测未来12个月市盈率约35倍。高盛指出，药明合联的无锡生产设施或会于明年第一季度迎来首次FDA检查，此前部分客户的BLA预料于2026年底前提交，将成为其全球商业化生产能力的重要验证里程碑。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-09-27/doc-initftkf9699013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EWH","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670460074","title":"高盛：药明合联(02268)商业化生产验证成为长期能见度关键催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2670460074","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670460074?lang=zh_cn&edition=full","pubTime":"2026-09-25 16:45","pubTimestamp":1790325927,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研报称，给予药明合联“买入”评级，目标价97.9港元，对应预测未来12个月市盈率约35倍。高盛指出，药明合联的无锡生产设施或会于明年第一季度迎来首次FDA检查，此前部分客户的BLA预料于2026年底前提交，将成为其全球商业化生产能力的重要验证里程碑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500940.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4504","BK1141","LU0326950275.SGD","LU1188198961.HKD","IE00BSNM7G36.USD","LU2237443549.SGD","LU0210536198.USD","LU0251131958.USD","LU2237443465.HKD","LU1868836591.USD","LU1791807156.HKD","BK4516","LU0096364046.USD","LU0244354667.USD","BK4585","LU0868494617.USD","LU2471134523.USD","LU2896262040.SGD","BK4127","BK4552","SG9999014674.SGD","IE00BFXG1179.USD","LU2237443382.USD","IE00B19Z3B42.SGD","LU0106831901.USD","IE0004086264.USD","LU1894683348.USD","LU2237443622.USD","LU2471134796.USD","LU0345770308.USD","LU2237438978.USD","LU1894683264.USD","LU2237443978.SGD","LU0463099449.HKD","GSX","LU0251142724.SGD","LU1868836914.USD","LU2471134879.HKD","BK4588","LU2750360997.AUD","LU2750360641.GBP","LU0061475181.USD","BK4533","LU0048573561.USD","IE00B19Z3581.USD","LU2488822045.USD","IE0002270589.USD","LU1668664300.SGD","LU1868837136.USD","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669451177","title":"生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2669451177","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669451177?lang=zh_cn&edition=full","pubTime":"2026-09-24 13:36","pubTimestamp":1790228201,"startTime":"0","endTime":"0","summary":"金吾财讯 |  港股生物医药板块午后全线走低，截至发稿，诺诚健华 跌10.48%，荣昌生物跌7.99%，复宏汉霖跌7.68%，康诺亚-B跌5.86%，再鼎医药跌5.32%，君实生物跌4.53%，金斯瑞生物科技跌4.21%，康方生物跌3.54%，科伦博泰生物跌3.11%，泰格医药跌2.35%，药明生物跌1.80%，百济神州跌1.56%，药明合联跌1.12%。消息面上，国盛证券发布研报称，医药行业需求尚未明显回暖，降本增效、费用精细化管理已成为利润端的重要支撑。下半年关注流感旺季带来的阶段性需求催化。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992441","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","BK1141","161726","LU0456846285.SGD","09969","LU1303224171.USD","LU1961090484.USD","LU0516422366.SGD","LU3063872942.SGD","LU1242518931.SGD","LU0516423174.USD","LU2399975544.HKD","LU1242518857.USD","06160","LU1719994722.HKD","LU0540923850.HKD","LU0348825331.USD","BK4581","09995","LU0348783233.USD","SG9999014674.SGD","01877","01548","BK1576","LU0856984785.SGD","LU1880383366.USD","LU2328871848.SGD","LU0828237510.HKD","LU0140636845.USD","HK0000306701.USD","06990","399441","02269","LU2039709279.SGD","SG9999002463.SGD","BK1515","BK1583","LU0561508036.HKD","02162","02696","KURE","LU1770034418.SGD","SG9999002562.SGD","03347","09926","LU0348766576.USD","688428","02268","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188227323","title":"创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188227323","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188227323?lang=zh_cn&edition=full","pubTime":"2026-09-23 11:01","pubTimestamp":1790132509,"startTime":"0","endTime":"0","summary":"9月23日，创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%，康方生物、诺诚健华涨逾3%，基石药业涨逾2%，百济神州、药明生物、君实生物涨逾1%，信达生物跟涨。9月12-15日2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3 ADC等成为焦点；与此同时，2026年国家医保目录谈判收官，商保创新药目录同步推进，支付端改革预期升温，\"出海商业化+支付改善\"的产业逻辑持续强化。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622","01672","02137","02269","03347","03759","09688","09995","01801","06606","06996","02359","02268","09606","09966","06618","06978","00241"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1153938851","title":"港股生物医药股全线大涨，金斯瑞涨超6%，药明康德涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153938851","media":"老虎快讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153938851?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:14","pubTimestamp":1789956879,"startTime":"0","endTime":"0","summary":"港股市场生物医药股全线大涨，其中，复宏汉霖涨超10%，君实生物、康方生物涨超8%，康诺亚-B、诺诚健华涨超7%，荣昌生物、金斯瑞生物科技、药明生物、科伦博泰生物涨超6%，药明康德、泰格医药、药明合联涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","01877","09926","09969","09995","01548","02162","06990","02359","02696","03347","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669136031","title":"生物医药板块盘初普升 复宏汉霖（02696）涨7.96% 机构指中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2669136031","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669136031?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:49","pubTimestamp":1789955355,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药板块盘初普升，截至发稿，复宏汉霖 涨7.96%，诺诚健华涨7.34%，荣昌生物涨6.69%，康诺亚-B涨6.52%，康方生物涨6.46%，君实生物涨6.41%，金斯瑞生物科技涨5.80%，科伦博泰生物涨5.63%，药明生物涨4.47%，药明康德涨2.90%，泰格医药涨2.69%，百济神州涨2.07%，药明合联涨1.75%。中信证券表示，中国创新药进入全球价值兑现阶段，头部国际化创新药企业有望迎来产品全球价值兑现期。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992049","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","LU0196878994.USD","161726","09969","LU0516422952.EUR","LU1961090484.USD","LU0348767384.USD","02359","06990","BK1515","LU0348766576.USD","LU0561508036.HKD","XBI","02269","BK1588","BK1610","LU0540923850.HKD","LU0463099449.HKD","LU1303224171.USD","01877","LU0348784397.USD","399441","LU0052750758.USD","KURE","LU0456827905.SGD","BK4588","LU0029874905.USD","02696","LU0320764243.SGD","03347","LU0244354667.USD","LU1880383366.USD","09926","LU1188198961.HKD","HK0000165453.HKD","LU2242644610.SGD","LU0326950275.SGD","LU0128522744.USD","LU2476274720.SGD","LU0979878070.USD","LU0327786744.USD","09995","LU0320764599.SGD","06160","LU2045819591.USD","LU0634319403.HKD","02162","LU2488822045.USD","01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153530578","title":"药明合联2026年中期营收37.01亿元，经调整净利润10.27亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153530578","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153530578?lang=zh_cn&edition=full","pubTime":"2026-09-18 17:35","pubTimestamp":1789724123,"startTime":"0","endTime":"0","summary":"2026年上半年，药明合联实现营收人民币37.01亿元，同比增长37.0%。同期，经调整净利润为人民币10.27亿元，同比上升37.4%，经调整净利率稳定在27.8%。公司报告期内毛利为13.71亿元，较上年同期增长40.6%，毛利率由36.1%进一步提升至37.0%。经营活动产生的现金净流入为11.87亿元。公司整体销售及营销开支为人民币64.4百万元，较上年同期增长31.3%；行政及其他开支上涨39.7%，达到人民币150.7百万元；研发开支为人民币81.9百万元，同比上涨65.6%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联2026年中期营收37.01亿元，经调整净利润10.27亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668993356","title":"【千亿药企龙头深度拆解】药明系：上市主体的资本与产业实验","url":"https://stock-news.laohu8.com/highlight/detail?id=2668993356","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668993356?lang=zh_cn&edition=full","pubTime":"2026-09-17 16:05","pubTimestamp":1789632300,"startTime":"0","endTime":"0","summary":"李革联合私募基金，以约33亿美元将药明康德从纽交所私有化退市。退市不是终点，而是重新切割业务、分批资本化的起点。药明生物是从药明康德大分子板块独立出来的公司，主业是大分子生物药CRDMO，包括抗体、双抗、融合蛋白、疫苗等生物药的研发与生产。药明合联的价值，正是依托药明生物的大分子平台、药明康德/合全药业的小分子平台，完成偶联、制剂与规模化生产，实现整套链条协同。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650514222&idx=1&sn=a5888f47603d14bfee478c846e35b8f0&chksm=f321e62ca04295728bbd6dcb9b1f75e4de3b57897423b59c2fa696ad13c6ef57c2cb3924a020&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["01875","LU1023057109.AUD","02269","LU0039217434.USD","02359","LU0326950275.SGD","LU0348827113.USD","LU0469268626.HKD","LU0588546209.SGD","01801","LU0708995583.HKD","LU1188198961.HKD","LU1880383366.USD","LU2125910500.SGD","LU2045819591.USD","LU0244354667.USD","LU0463099449.HKD","LU0856984785.SGD","BK1141","LU0502904849.HKD","LU1794554557.SGD","LU1720050803.USD","LU0320764243.SGD","02268","HK0000165453.HKD","LU2097828557.USD","03347","BK1583","LU0348766576.USD","LU1046422090.SGD","LU2242644610.SGD","LU0128526141.USD","LU0359202008.SGD","BK1191","LU0823426480.USD","02126","IE00B0JY6N72.USD","LU0128522744.USD","LU0327786744.USD","01276","LU2039709279.SGD","LU0029874061.USD","LU0149534421.HKD","LU0540923850.HKD","LU2097828631.EUR","KURE","LU0516422440.USD","03759","LU0417516738.SGD","LU0819121731.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138757348","title":"异动解读｜药明合联盘中上涨3.01%，国际资管巨头Schroders增持突破5%举牌线","url":"https://stock-news.laohu8.com/highlight/detail?id=1138757348","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138757348?lang=zh_cn&edition=full","pubTime":"2026-09-17 09:54","pubTimestamp":1789610079,"startTime":"0","endTime":"0","summary":"9月17日，药明合联盘中上涨3.01%，报77.45港元/股，成交额8474.68万港元。消息面上，联交所权益披露显示，Schroders PLC于9月14日以每股约75.66港元增持药明合联39.45万股，涉资约2984.68万港元，持股比例由4.98%升至5.01%，触及举牌线。值得注意的是，Schroders近期围绕5%关口反复操作，8月底曾减持至4.99%后于8月31日再度增持至5.03%，显示其对公司中长期价值的持续关注。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明合联获国际巨头举牌，股价应声上涨","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667538988","title":"Schroders PLC增持药明合联(02268)39.45万股 每股作价约75.66港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667538988","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667538988?lang=zh_cn&edition=full","pubTime":"2026-09-16 19:44","pubTimestamp":1789559049,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，9月14日，Schroders PLC增持药明合联(02268)39.45万股，每股作价75.6574港元，总金额约为2984.68万港元。增持后最新持股数目为6353.9万股，最新持股比例为5.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496972.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0463099449.HKD","LU2488822045.USD","LU0244354667.USD","EWH","02268","SG9999014674.SGD","BK1141","LU0326950275.SGD","LU1188198961.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192607013","title":"药明合联：Schroders PLC增持，好仓比例升至5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192607013","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192607013?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:15","pubTimestamp":1789550117,"startTime":"0","endTime":"0","summary":"Schroders PLC于2026年9月14日在联交所场内以每股均价75.6574港元买入药明合联股份39.45万股，涉资约2984.68万港元，属场内主动交易，即在二级市场直接买卖股份。Schroders PLC此次增持前持有药明合联好仓6314.45万股，占比4.98%；增持后持股量为6353.90万股，好仓比例升至5.01%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147478325","title":"异动解读｜药明合联盘中上涨3.81%，板块集体反弹叠加中报业绩支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=1147478325","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147478325?lang=zh_cn&edition=full","pubTime":"2026-09-14 11:29","pubTimestamp":1789356554,"startTime":"0","endTime":"0","summary":"9月14日，药明合联盘中上涨3.81%，报74.85港元/股，成交额1.42亿港元。消息面上，此前药明康德及关联方通过大宗交易出售药明合联约5352.4万股，持股比例由18.36%降至14.14%，减持抛压一度令股价连续走弱。板块方面，生命科学工具和服务行业今日集体走强，康龙化成涨5.66%，金斯瑞生物科技涨5.07%，药明生物涨4.55%，药明康德涨4.08%，板块联动效应显著。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明合联异动上涨，业绩订单双增引关注","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667631824","title":"高盛：中国CRO/CDMO行业复苏步伐明确 看好药明系等","url":"https://stock-news.laohu8.com/highlight/detail?id=2667631824","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667631824?lang=zh_cn&edition=full","pubTime":"2026-09-14 09:38","pubTimestamp":1789349915,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2045819591.USD","LU2125910500.SGD","LU0052750758.USD","02268","06821","LU0572944931.SGD","LU0244354667.USD","03759","BK1576","LU1188198961.HKD","BK1583","LU0708995583.HKD","LU2488822045.USD","LU0327786744.USD","LU0348766576.USD","BK1141","BK1191","02359","LU2242644610.SGD","LU0348767384.USD","LU0320764599.SGD","LU1046422090.SGD","LU0463099449.HKD","SG9999014674.SGD","LU0469268626.HKD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139727960","title":"异动解读｜药明合联盘中下跌3.42%，母公司大额减持抛压持续叠加板块走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1139727960","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139727960?lang=zh_cn&edition=full","pubTime":"2026-09-11 09:47","pubTimestamp":1789091265,"startTime":"0","endTime":"0","summary":"9月11日，药明合联盘中下跌3.42%，报70.3港元/股，成交额4752.96万港元。消息面上，药明康德及其关联方近期通过大宗交易出售药明合联约5352.4万股，成交均价73.23港元，涉资约39.2亿港元，持股比例由18.36%降至14.14%，预计产生税前投资收益约31.43亿元。大股东及机构的集中减持对短期股价形成持续抛压。板块方面，生命科学工具和服务行业今日多数走弱，药明生物跌2.53%，药明康德跌1.78%，英矽智能跌5.1%，晶泰控股跌4.72%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药明合联遭大额减持，股价承压走弱","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146603275","title":"异动解读｜药明合联盘中下跌3.29%，母公司大额减持叠加板块整体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1146603275","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146603275?lang=zh_cn&edition=full","pubTime":"2026-09-10 13:48","pubTimestamp":1789019289,"startTime":"0","endTime":"0","summary":"9月10日，药明合联盘中下跌3.29%，报71.95港元/股，成交额1.72亿港元。消息面上，药明康德及其关联方近期通过大宗交易出售药明合联约5352.4万股，成交均价73.23港元，涉资约39.2亿港元，持股比例由18.36%降至14.14%，预计产生税前投资收益约31.43亿元。大股东及机构的集中减持对短期股价形成抛压。板块方面，生命科学工具和服务行业今日整体走弱，金斯瑞生物科技跌4.16%，药明生物跌3.15%，药明康德跌0.78%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药明合联遭大额减持，股价承压走弱","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108386564","title":"异动解读｜药明合联盘中上涨3.17%，报74.85港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108386564","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108386564?lang=zh_cn&edition=full","pubTime":"2026-09-08 13:13","pubTimestamp":1788844416,"startTime":"0","endTime":"0","summary":"9月8日，药明合联盘中上涨3.17%，报74.85港元/股，成交额1.18亿港元。药明合联所在的生命科学工具和服务行业中，个股普遍走强，其中英矽智能涨9.11%，金斯瑞生物科技涨9.03%，晶泰控股涨0.77%，药明康德涨0.73%，药明生物涨0.58%。药明合联生物技术有限公司是一家主要从事抗体偶联药物（ADC）及其他生物偶联药物的全面合同研究、开发及制造组织（CRDMO）服务的投资控股公司，主要在国内市场、北美、欧洲和世界其他地区市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://wuxixdc.com","stockEarnings":[{"period":"1week","weight":-0.031},{"period":"1month","weight":0.0634},{"period":"3month","weight":0.3681},{"period":"6month","weight":0.2764},{"period":"1year","weight":0.0393},{"period":"ytd","weight":0.2848}],"compareEarnings":[{"period":"1week","weight":-0.0225},{"period":"1month","weight":-0.0415},{"period":"3month","weight":0.0718},{"period":"6month","weight":-0.0236},{"period":"1year","weight":-0.0789},{"period":"ytd","weight":-0.0432}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明合联生物技术有限公司是一家主要从事提供提供抗体偶联药物（ADC）及其他生物偶联药物的全面合同研究、开发及制造组织（CRDMO）服务的投资控股公司。该公司的服务包括生物偶联药物、单克隆抗体中间体及生物偶联药物相关连接子及有效载荷的发现、工艺开发及优良生产质量管理规范（GMP）生产。该公司透过按有偿服务（FFS）基准的合约和按全时当量（FTE）基准的合约向客户提供CRDMO服务。该公司主要在国内市场、北美、欧洲和世界其他地区市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":0.010265},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058284},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010372},{"month":4,"riseRate":0.555556,"avgChangeRate":0.03555},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006014},{"month":6,"riseRate":0.4,"avgChangeRate":-0.032735},{"month":7,"riseRate":0.4,"avgChangeRate":0.011785},{"month":8,"riseRate":0.4,"avgChangeRate":-0.114063},{"month":9,"riseRate":0.333333,"avgChangeRate":0.019767},{"month":10,"riseRate":0.777778,"avgChangeRate":0.151657},{"month":11,"riseRate":0.333333,"avgChangeRate":0.008796},{"month":12,"riseRate":0.111111,"avgChangeRate":-0.068876}],"exchange":"SEHK","name":"药明合联","nameEN":"WUXI XDC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明合联,02268,药明合联股票,药明合联股票老虎,药明合联股票老虎国际,药明合联行情,药明合联股票行情,药明合联股价,药明合联股市,药明合联股票价格,药明合联股票交易,药明合联股票购买,药明合联股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}